analysts
Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical
Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership
Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed
Systemic Scleroderma, Lupus Erythematosus, Systemic, Cabaletta, cell-associated neurotoxicity, Adverse effects, analysts, Autoimmune Diseases, CAR-T therapy, reSET (device), aspects of adverse effects, Cytokine Release Syndrome
Unitys eye treatment fails to match Eylea, though analysts still see a path forward
analysts, Eylea, match Eylea, Macular edema due to diabetes mellitus